Volume 10, Number 10—October 2004
Research
Sulfa Use, Dihydropteroate Synthase Mutations, and Pneumocystis jirovecii Pneumonia
Table 2
Study characteristica | Characteristic level | No. of studies | RD (95% CLD)b | Homogeneity test p value | Difference of RDs (95% CLD)b |
---|---|---|---|---|---|
Prophylaxis effect on mutation | |||||
Data collection calendar midpoint | 1996 or later | 6 | 0.22 (0.31) | < 0.001 | –0.32 (0.39) |
Before 1996 | 7 | 0.53 (0.18) | 0.8 | 0 | |
4-y change | 13 | NA | NA | –0.23 (0.30) | |
Prophylaxis use by | |||||
Specific mutations | Yes | 4 | 0.54 (0.24) | 0.6 | 0.20 (0.55) |
No | 9 | 0.32 (0.29) | < 0.001 | 0 | |
Multiple isolates per patient | Yes | 5 | 0.50 (0.50) | < 0.001 | 0.19 (0.52) |
No | 8 | 0.30 (0.32) | < 0.001 | 0 | |
Location | USA | 5 | 0.44 (0.43) | < 0.001 | 0.10 (0.55) |
Outside USA | 8 | 0.34 (0.36) | < 0.001 | 0 | |
Defined treatment outcome | Yes | 5 | 0.32 (0.44) | < 0.001 | –0.08 (0.54) |
No | 8 | 0.41 (0.35) | < 0.001 | 0 | |
Multicenter | Yes | 5 | 0.41 (0.31) | 0.0 | 0.05 (0.55) |
No | 8 | 0.36 (0.36) | < 0.001 | 0 | |
Proportion HIV+ | 1.00 | 8 | 0.38 (0.30) | < 0.001 | 0.03 (0.56) |
< 1.00 | 5 | 0.37 (0.58) | < 0.001 | 0 |
aData collection calendar midpoint, the midpoint in calendar time of data collection; defined treatment outcome, whether the study stated how it defined treatment outcome.
bRD, risk difference; CLD, confidence limit difference; NA, not applicable.
Page created: April 11, 2011
Page updated: April 11, 2011
Page reviewed: April 11, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.